
879088-41-2 Vismodegib Intermediate
Product name:4-chloro-3-(pyridin-2-yl)anilineCAS:879088-41-2. MF:C11H9ClN2. MW:204.66. EINECS:. MDL No.:MFCD12024455
Add to Inquiry
CAS 5516-88-1 | Paspalic Acid
Name: Ergoline-8-carboxylic acid, 8,9-dihydro-6-methyl-CAS number: 5516-88-1Molecular formula: C16H16N2O2Molecular weight: 268.31EINECS number:MDL No.:
Add to Inquiry
CAS 2861-28-1 | 3,4-(Methylenedioxy)phenylacetic Acid
Name: 3,4-(METHYLENEDIOXY) PHENYLACETIC ACIDCAS number: 2861-28-1Molecular formula: C9H8O4Molecular weight: 180.16EINECS number: 220-679-9MDL No.:MFCD00014576
Add to Inquiry
CAS 109555-87-5 | 3-(1-Naphthoyl)indole
Name: 3- (1-Naphthoyl) indoleCAS number: 109555-87-5Molecular formula: C19H13NOMolecular weight: 271.31EINECS number: 207-791-3MDL No.:MFCD12923093
Add to Inquiry![943516-54-9 6,6-dimethyl-3-azabicyclo-[3.1.0]hexane](/uploads/41320/small/943516-54-97d6ba.jpg)
943516-54-9 6,6-dimethyl-3-azabicyclo-[3.1.0]hexane
CAS:943516-54-9MF:C7H13NMW:111.18EINECS:1308068-626-2MDL No.:MFCD13176114
Add to Inquiry
82419-35-0 Oxygen-fluorine Acid
CAS:82419-35-0MF:C13H9F2NO4MW:281.21EINECS:700-160-8MDL No.:MFCD00226106
Add to Inquiry
3105-95-1 L-pipecolic Acid
Product name: L-pipecolic acidCAS number: 3105-95-1Molecular formula: C6H11NO2Molecular weight: 129.16EINECS number: 221-462-1MDL No.:MFCD00005981
Add to Inquiry
719-59-5 2-Amino-5-chlorobenzophene
Product name: 2-Amino-5-chlorobenzopheneCAS number: 719-59-5Molecular formula: C13H10ClNOMolecular weight: 231.68EINECS number: 211-949-7MDL No.:MFCD00007839
Add to Inquiry
505-54-4 HEXADECANEDIOIC ACID
Product name: HEXADECANEDIOIC ACIDCAS number: 505-54-4Molecular formula: C16H30O4Molecular weight: 286.41EINECS number: 208-013-5MDL No.:MFCD00002746
Add to Inquiry
843666-27-3
Product name: 16-(Tert butoxy)-16-oxohexadecanoic acidCAS number: 843666-27-3Molecular formula: C20H38O4Molecular weight: 342.51EINECS number:MDL No.:MFCD23136039
Add to Inquiry
109-12-6 2-aminopyrimidine
Product name:2-aminopyrimidineCAS:109-12-6. MF:C4H5N3. MW:95.1. EINECS:203-648-4. MDL No.:MFCD00006089
Add to Inquiry
3-quinuclidinone Hydrochloride 1193-65-3
CAS:1193-65-3. MF:C7H12ClNO. MW:161.63. EINECS:214-776-5. MDL No.:MFCD00137391
Add to Inquiry
China Vismodegib intermediate Manufacturers Factory Suppliers
We are a professional integrated system intermediate, complementary intermediate, Pazopanib intermediate manufacturer integrating development, design, production and sales, and our products reflect the characteristics of the times.We believe we will be able to bring you the most satisfactory Vismodegib intermediate and services based on the principle of excellence, honesty and customer first. We are committed to ensuring the satisfaction of our customers, no matter what. "Professional quality, low price, good quality and considerate service" is our consistent purpose. We sincerely look forward to working with you to create a better future. We have a perfect quality inspection system to ensure the qualification rate of our products, and some of them have successfully entered the international market. We regulate people with strict rules and regulations, demand people with rigorous work style, guide people with noble moral sentiment and unite people with harmonious humanistic atmosphere. Since its establishment, we have served every customer with the principle of "customer first, honesty first", so we have gained the full trust of many customers.WEBSep 24, 2018 · In this phase Ib study, ten patients with intermediate- or high-risk primary or secondary MF received open-label vismodegib (150 mg/day orally) and ruxolitinib (15 or 20 mg orally...
WEBSep 24, 2018 · Methods: In this phase Ib study, ten patients with intermediate- or high-risk primary or secondary MF received open-label vismodegib (150 mg/day orally) and ruxolitinib (15 or 20 mg...
WEBDec 7, 2017 · Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis | Blood |...
WEBPublished: 20 December 2019. Clinical Study. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic......
WEBJun 7, 2012 · A phase 1 study of vismodegib involving 33 patients with advanced basal-cell carcinoma showed a 58% confirmed response rate and a median duration of response of 12.8 months. 4,5 This...
WEBNov 30, 2018 · Methods: In this phase Ib study, ten patients with intermediate- or high-risk primary or secondary MF received open-label vismodegib (150 mg/day orally) and ruxolitinib (15 or 20 mg...
